mutation braf gene valine v substituted glutamic acid e amino acid driver mutation proportion certain diagnoses including hairy cell papillary thyroid colorectal nonsmallcell lung langerhans cell disease nonlangerhanscell histiocytosis mechanism mutation negative charge acidic glutamic acid residue causes phosphomimetic mimics phosphorylation nearby threonine serine residues activation segment braf used activate wild type form protein glutamate residue mutant therefore functions activate braf inhibiting interaction brafs glycine rich loop activation segment would ordinarily inhibitory loss inhibition braf leads increase basal activity hence oncogenic vemurafenib encorafenib dabrafenib approved fda treatment metastatic melanomas express ec enzymerelated article stub help wikipedia expanding